Lianbo Gao
The Fourth Affiliated Hospital of China Medical University · the Fourth Affilicated Hospital of China Medical University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lianbo Gao as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:05 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06857045 · Comparison Three vs Six Months of Dual Anti-platelet Therapy After Sirolimus-eluting Stent ImplantationSino Medical Sciences Technology Inc. · withdrawn · Intracranial Arteriosclerosis, Intracranial Artery Stenosis, Drug-Eluting Stents · principal investigator
- N/ANCT06301776 · A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting BridgeThe Fourth Affiliated Hospital of China Medical University · unknown · Brain Disease, Vertebral Artery Stenosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:05 UTC. The ranking covers the 200 most relevant of 502 PubMed records, and a shared surname and initials can bring in a namesake. All 502 on PubMed
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.Lancet · 20202,489 citationsRCR 131.1
- 1,744 citationsRCR 52.4
- Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.N Engl J Med · 20161,561 citationsRCR 57.8
- Ustekinumab induction and maintenance therapy in refractory Crohn's disease.N Engl J Med · 2012931 citationsRCR 26.4
- 269 citationsRCR 22.9
- Effects and costs of real-time cardiac telerehabilitation: randomised controlled non-inferiority trial.Heart · 2019245 citationsRCR 13.9
- Middle Meningeal Artery Embolization for Nonacute Subdural Hematoma.N Engl J Med · 2024220 citationsRCR 62.0
- 217 citationsRCR 12.3
- A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer.Invest New Drugs · 2015167 citationsRCR 6.3
- 146 citationsRCR 5.9